PPT1 and hepatocellular carcinoma: The research further revealed that HCC patients with low intra-tumoral PPT1+ macrophage infiltration tend to have a survival advantage, indicating that targeting PPT1 may serve as an immunotherapeutic biomarker in HCC (Weng et al., 2023).